RecruitingNot ApplicableNCT06916208

Study of the Effect of Capsinoid Supplementation on Brown Adipose Tissue in Obese Adolescents


Sponsor

University of Avignon

Enrollment

38 participants

Start Date

Mar 3, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Among the new strategies being considered for the treatment of obesity and its metabolic complications, the activation of brown adipose tissue (BAT) from white adipose tissue looks promising. Interest in the study of BAT has increased over the last 5-10 years in response to the discovery of functional BAT in humans. The BAT is a tissue specialized in regulating energy expenditure by producing heat through the oxidation of fatty acids contained in the multiple lipid droplets of brown adipocytes. This adipose tissue does not play a storage role, but rather an anti-obesogenic one, thanks to its high metabolic and energetic activity. In addition to exposure to cold, which is the major physiological inducer of brown adipocytes, it seems that exercise and the intake of "adrenergic" foods can activate the TAB and potentially induce a change from white to brown tissue via the production of adrenalin and myokines. Acute and/or chronic effects of thermogenic food supplements have been reported on BAT activation and energy metabolism. The most conclusive of these involve the capsinoids found in sweet peppers and chillies. Weight loss also improves BAT activation. The BAT has already been identified in children. A decrease in its volume and activity from childhood to adolescence and during puberty has been reported. The main objective of this randomized controlled double-blind study is to investigate the effects of capsinoid dietary supplementation on BAT activity in obese adolescents. Our general working hypothesis is that capsinoid supplementation, combined with dietary management, leads to an increase in BAT activity.


Eligibility

Min Age: 11 YearsMax Age: 18 Years

Inclusion Criteria4

  • member or beneficiary of a health insurance scheme
  • aged between 11 and 18
  • Body Mass Index Z score corresponding to stage 2 obesity according to the curves of Rolland-Cachera et al., 1991 and an absence of weight loss of more than 5% of the total weight over the last 3 months.
  • effective contraception (in pubescent females)

Exclusion Criteria6

  • known allergy to capsinoids and/or soya
  • inflammatory digestive pathology and/or history of digestive tract surgery
  • participation in another study or in a period of exclusion determined by a previous study
  • pregnant, parturient or breastfeeding
  • The holder(s) of parental authority or the adolescent refuse(s) to sign the authorisation or acceptance form, respectively.
  • It proves impossible to provide the adolescent or parental guardian(s) with informed information.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTcapsinoid supplementation

Adolescents in the experimental group will receive active capsules containing dihydrocapsiate (bought from Ajinomoto® (Ajinomoto Health \& Nutrition North America, Inc., Japan) 3 times per day, representing 9mg/day all through the duration of the 4-week multidimensional care program.

OTHERControl group (placebo)

Regular multidimensional care 4-week program


Locations(1)

Institut Saint Pierre

Palavas-les-Flots, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06916208


Related Trials